Overlap of aca-positive systemic sclerosis and Sjögren's syndrome: A distinct clinical entity with mild organ involvement but at high risk of lymphoma

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0273-0280

  Baldini, Chiara ^a   Mosca, Marta ^a   Della Rossa, Alessandra ^a   Pepe, Patrizia ^a   Notarstefano, Chiara ^a   Ferro, Francesco ^a   Luciano, Nicoletta ^a   Talarico, Rosaria ^a   Tani, Chiara ^a   Tavoni, Antonio G ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Lymphoma; Sj gren's syndrome; systemic sclerosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LA ANTIBODY; PREDNISOLONE; PROSTACYCLIN; RHEUMATOID FACTOR; RO ANTIBODY; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; SS A ANTIBODIES; SS B ANTIBODIES; SS-A ANTIBODIES; SS-B ANTIBODIES;

ADULT; ARTHRALGIA; ARTICLE; CANCER RISK; CAPILLAROSCOPY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PURPURA; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; SCLERODACTYLY; SJOEGREN SYNDROME; SKIN DISEASE; SYSTEMIC SCLEROSIS; ANALYSIS OF VARIANCE; BLOOD; CHI SQUARE DISTRIBUTION; IMMUNOLOGY; ITALY; LIMITED SCLERODERMA; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; HUMANS; ITALY; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, LIMITED; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

MLCS; MLOWN;

EID: 84875797968     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. MOSCA M, NERI R, BOMBARDIERI S: Undifferentiated connective tissue diseases (UCTD): A review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999; 17: 615-20.
2. MOSCA M, TANI C, NERI C, BALDINI C, BOMBARDIERI S: Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006; 6: 1-4.
3. MOSCA M, TANI C, TALARICO R, BOMBARDIERI S: Undifferentiated connective tissue diseases (UCTD): Simplified systemic autoimmune diseases. Autoimmun Rev 2011; 10: 256-8.
4. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Undifferentiated CTD: A wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26: 73-7.
5. CAPPELLI S, BELLANDO RANDONE S, MARTINOVIC D et al.: "To be or not to be," ten years after: Evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41: 589-98.
6. MOSCA M, BALDINI C, BOMBARDIERI S: Undifferentiated connective tissue diseases in 2004. Clin Exp Rheumatol 2004; 22 (Suppl. 33): S14-8.
7. TZIOUFAS AG, VOULGARELIS M: Update on Sjögren's syndrome autoimmune epithelitis: From classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007; 21: 989-1010.
8. BALDINI C, PEPE P, LUCIANO N et al.: A clinical prediction rule for lymphoma development in primary Sjögren's syndrome. J Rheumatol 2012; 39: 804-8.
9. BLOCH KJ, BUCHANAN WW, WOHL MJ, BUNIM JJ: Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965; 44: 187-231.
10. AVOUAC J, SORDET C, DEPINAY C et al.: Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006; 54: 2243-9.
11. AVOUAC J, AIRO P, DIEUDE P et al.: Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: Results from 2 large cohorts of european caucasian patients. J Rheumatol 2010; 37: 608-14.
12. SALLIOT C, MOUTHON L, ARDIZZONE M et al.: Sjögren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) 2007; 46: 321-6.
13. SALLIOT C, GOTTENBERG JE, BENGOUFA D, DESMOULINS F, MICELI-RICHARD C, MARIETTE X: Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol 2007; 34: 2253-8.
14. SWAMINATHAN S, GOLDBLATT F, DUGAR M, GORDON TP, ROBERTS-THOMSON PJ: Prevalence of sicca symptoms in a South Australian cohort with systemic sclerosis. Intern Med J 2008; 38: 897-903.
15. HASHIMOTO A, TEJIMA S, TONO T et al.: Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011; 38: 1931-9.
16. HERNANDEZ-MOLINA G, AVILA-CASADO C, CARDENAS-VELAZQUEZ F et al.: Similarities and differences between primary and secondary Sjögren's syndrome. J Rheumatol 2010; 37: 800-8.
17. MIYAWAKI S, ASANUMA H, NISHIYAMA S, YOSHINAGA Y: Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005; 32: 1488-94.
18. VLACHOYIANNOPOULOS PG, DROSOS AA, WIIK A, MOUTSOPOULOS HM: Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 1993; 32: 297-301.
19. CARAMASCHI P, BIASI D, CARLETTO A et al.: Sjögren's syndrome with anticentromere antibodies. Rev Rhum Engl Ed 1997; 64: 785-8.
20. PAKOZDI A, NIHTYANOVA S, MOINZADEH P, ONG VH, BLACK CM, DENTON CP: Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406-9.
21. BOURNIA VK, DIAMANTI KD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOS HM: Anticentromere antibody positive Sjögren's syndrome: A retrospective descriptive analysis. Arthritis Res Ther 2010; 12: R47.
22. RAMOS-CASALS M, BRITO-ZERON P, FONT J: The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 2007; 36: 246-55.
23. RAMOS-CASALS M, NARDI N, BRITO-ZERON P et al.: Atypical autoantibodies in patients with primary Sjögren's syndrome: Clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006; 35: 312-21.
24. KITAGAWA T, SHIBASAKI K, TOYA S: Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren's syndrome. Clin Rheumatol 2012; 31: 105-12.
25. BALDINI C, TALARICO R, TZIOUFAS AG, BOMBARDIERI S: Classification criteria for Sjögren's syndrome: A critical review. J Autoimmun 2012; 39: 9-14.
26. RAMOS-CASALS M, BRITO-ZERON P, PEREZDE- LIS M et al.: Sjögren's syndrome or Sjögren's disease? The histological and immunological bias caused by the 2002 criteria. Clin Rev Allergy Immunol 2010; 38: 178-85.
27. BALDINI C, GIUSTI L, BAZZICHI L, LUCACCHINI A, BOMBARDIERI S: Proteomic analysis of the saliva: A clue for understanding primary from secondary Sjögren's syndrome? Autoimmun Rev 2008; 7: 185-91.
28. BALDINI C, GIUSTI L, CIREGIA F et al.: Proteomic analysis of saliva: A unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res Ther 2011; 13: R194.
29. GIUSTI L, BAZZICHI L, BALDINI C et al.: Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 2007; 34: 2063-9.
30. GIUSTI L, BALDINI C, BAZZICHI L, BOMBARDIERI S, LUCACCHINI A: Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics 2007; 4: 757-67.
31. BALDINI C, GIUSTI L, BAZZICHI L et al.: Association of psoriasin (s100a7) with clinical manifestations of systemic sclerosis: Is its presence in whole saliva a potential predictor of pulmonary involvement? J Rheumatol 2008; 35: 1820-4.
32. TANDON M, GALLO A, JANG SI, ILLEI GG, ALEVIZOS I: Deep sequencing of short rnas reveals novel micrornas in minor salivary glands of patients with Sjögren's syndrome. Oral Dis 2012; 18: 127-31.
33. GALLO A, TANDON M, ALEVIZOS I, ILLEI GG: The majority of micrornas detectable in serum and saliva is concentrated in exosomes. PLoS One 2012; 7: e30679.
34. FERRACCIOLI G, DE SANTIS M, PELUSO G et al.: Proteomic approaches to Sjögren's syndrome: A clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev 2010; 9: 622-6.
35. GALLO A, BALDINI C, TEOS L, MOSCA M, BOMBARDIERI S, ALEVIZOS I: Emerging trends in Sjögren's syndrome: Basic and translational research. Clin Exp Rheumatol 2012: 30: 779-84 [Epub Oct 17].
36. BALDINI C, GALLO A, PEREZ P, MOSCA M, ALEVIZOS I, BOMBARDIERI S: Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. Clin Exp Rheumatol 2012: 30: 785-90 [Epub Oct 17].
37. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 1980; 23: 581-90.
38. LEROY EC, MEDSGER TA, JR.: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
39. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002; 61: 554-8.
40. AVOUAC J, FRANSEN J, WALKER UA et al.: Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi Consensus Study from EULAR scleroderma trials and research group. Ann Rheum Dis 2011; 70: 476-81.
41. HARDING S, KHIMDAS S, BONNER A, BARON M, POPE J: Best practices in scleroderma: an analysis of practice variability in ssc centres within the Canadian scleroderma research group (CSRG). Clin Exp Rheumatol 2012; 30 (Suppl. 71): S38-43.
42. POPE J, HARDING S, KHIMDAS S, BONNER A, BARON M: Agreement with guidelines from a large database for management of systemic sclerosis: Results from the Canadian scleroderma research group. J Rheumatol 2012; 39: 524-31.
43. KHANNA D, KOWAL-BIELECKA O, KHANNA PP et al.: Quality indicator set for systemic sclerosis. Clin Exp Rheumatol 2011; 29: S33-9.
44. SEROR R, RAVAUD P, BOWMAN SJ et al.: Eular Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
45. GARCIA-CARRASCO M, RAMOS-CASALS M, ROSAS J et al.: Primary Sjögren's syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81: 270-80.
46. PERTOVAARA M, PUKKALA E, LAIPPALA P, MIETTINEN A, PASTERNACK A: A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: Clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001; 60: 467-72.
47. RAMOS-CASALS M, SOLANS R, ROSAS J et al.: Primary Sjögren's syndrome in spain: Clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-9.
48. ALBRECHT J, ATZENI F, BALDINI C et al.: Skin involvement and outcome measures in systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24: S52-9.
49. CHISHOLM DM, MASON DK: Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968; 21: 656-60.
50. GALIE N, HOEPER MM, HUMBERT M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-63.
51. MANOUSSAKIS MN, GEORGOPOULOU C, ZINTZARAS E et al.: Sjögren's syndrome associated with systemic lupus erythematosus: Clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 882-91.
52. DE VITA S, QUARTUCCIO L, SALVIN S, CORAZZA L, ZABOTTI A, FABRIS M: Cryoglobulinaemia related to Sjögren's syndrome or hcv infection: Differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology (Oxford) 2012; 51: 627-33.
53. GULATI D, KUSHNER I, FILE E, MAGREY M: Primary Sjögren's syndrome with anticentromere antibodies-a clinically distinct subset. Clin Rheumatol 2010; 29: 789-91.
54. TOBON GJ, RENAUDINEAU Y, HILLION S et al.: The fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2010; 62: 3447-56.
55. QUARTUCCIO L, SALVIN S, FABRIS M et al.: Blys upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher essdai score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2012:
56. VOULGARELIS M, DAFNI UG, ISENBERG DA, MOUTSOPOULOS HM: Malignant lymphoma in primary Sjögren's syndrome: A multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. Arthritis Rheum 1999; 42: 1765-72.
57. VOULGARELIS M, ZIAKAS PD, PAPAGEORGIOU A, BAIMPA E, TZIOUFAS AG, MOUTSOPOULOS HM: Prognosis and outcome of non- Hodgkin lymphoma in primary Sjögren's syndrome. Medicine (Baltimore) 2012; 91: 1-9.
58. VETTORI S, STAIBANO S, MASCOLO M, ILARDI G, VALENTINI G: Non-Hodgkin's lymphoma in systemic sclerosis: Case and literature review. Clin Rheumatol 2010; 29: 1-6.